Category Archives: Scottsdale Plastic Surgeons

Sanofi – Résultats T2 2015 Interview du Directeur Général Olivier Brandicourt






PARIS, July 30, 2015 /PRNewswire/ —

Sanofi, un innovator mondial et diversifié de la santé, publie ses résultats pour le premier semestre 2015. Le Directeur Général Olivier Brandicourt commente les résultats.

Visionner linterview vidéo et lire la transcription : 

http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire

Au sommaire de linterview : 

– Résultats T2

– Moteurs de croissance

– Diabète

– Praluent

– Innovation

– Immuno-oncologie

A propos de Sanofi 

Sanofi, un innovator mondial de la santé, recherche, développe et commercialise des services thérapeutiques centrées sur les besoins des patients. Sanofi possède des atouts fondamentaux dans la prise en cost du diabète, les vaccins humains, les produits innovants, la santé grand public, les marchés émergents, la santé animale et Genzyme. Sanofi est coté à Paris (EURONEXT: SAN) et à New York (NYSE: SNY).

SOURCE Sanofi

Pantheon Healthcare Group Acquires IBSL, a Leading Provider of Clinical Engineering Services in Italy, from Gruppo Giglio






LUGANO, Switzerland, July 30, 2015 /PRNewswire/ —

Pantheon Holdco Ltd., doing business as the Pantheon Healthcare Group (“Pantheon”), announced today the acquisition of Ingegneria Biomedica Santa Lucia S.p.A. (“IBSL”), a vital Italian-based provider of Clinical Engineering and a large range of biomedical equipment services, from Gruppo Giglio.

Backed by the Permira Funds, the acquisition is section of Pantheon’s continued geographic and modality growth strategy, which launched in August 2014 along with the acquisition of Asteral Limited and MESA Group Holdings, two leading independent healthcare service companies operating within the European market. The combination developed Europe’s initial integrated multi-vendor healthcare service platform for procuring, commissioning, managing and maintaining biomedical devices and diagnostic imaging equipment within public- and private-sector hospitals and clinics.

IBSL was born in 1997 from the entrepreneurial pointer of Sergio and Bruno Giglio’s long customer-centric experience along with outsourcing selections for heating systems. Their biomedical business swiftly grew to become one of the leading Clinical Engineering service providers in Italy, providing direct maintenance to biomedical units within hospitals and clinics across Italy. In the ensuing years, IBSL integrated further management expertise and technical competences through the acquisition of D&D Med. Com., Ra.se.co, Gidea Alta Tecnologia and Te.Mo.Sa, further strengthening its placement in Clinical Engineering and expanding its reach in the sector of diagnostic imaging equipment and outsourcing services.

Thanks to a great managerial team, led by Alessandro Dogliani, Davide Gagliardi, Antonio Marino, Angelo Deantoni and Enrico Labella, with each other along with concerning 300 technicians and highly qualified engineers directly operating within hospitals, IBSL delivers higher quality, affordable Clinical Engineering services, comprehensive solutions for the supply and maintenance of diagnostic imaging equipment as well as full-service outsourcing opportunities for radiology departments, currently serving much more Compared to 60 hospitals, research facilities and others clinical providers in Italy.

The acquisition of IBSL strengthens Pantheon’s placement as a leading independent pan-European healthcare provider of finish managed solutions for the lifecycle of medical technologies. along with a durable concentrate on the maintenance, management and sale of equipment for hospitals and diagnostic centres, Pantheon provides central solutions for markets increasingly requiring comprehensive outsourcing provisions and managed services. The combination of IBSL and Pantheon will certainly extend the service offering of the Group, providing a wider variety of equipment services and products and strengthening Pantheon’s presence in Italy, a vital country for its worldwide business development.

Since its inception in August 2014, Pantheon has actually continued its growth both organically and though the acquisition of three vital vendor-independent higher technology equipment service providers: MVS in Poland, Spintech in Turkey, and Sigil in France.

Of the acquisition, Rob Piconi, Group CEO of Pantheon, commented, “We are delighted to announce the acquisition of IBSL in Italy. The Giglio family has actually built a distinctive and specialised business, which adds complementary skills and competences to our existing Pantheon team. Already present in 13 markets and growing while providing service to much more Compared to 600 hospitals and clinics, along with the addition of IBSL we are in an even stronger placement to offer much more integrated solutions and a broader portfolio of higher quality equipment service offerings to hospitals and diagnostic centres. Our goal for our clients remains the same: to deliver much better outcomes for patients and the most effective continued care through efficient application of our service delivery platform.”

Facing a Brand-new phase in Gruppo Giglio’s development, Sergio Giglio added, “The market is changing and constantly transforming as our clients’ need is evolving. To know exactly how to modification and evolve is fundamental, in products, services and likewise in the structure of the company. This phase will certainly be characterised by the introduction of a much more managerial model, in step along with times, prepared to face the challenges of the future, along with durable thanks to the collaboration of higher quality engineering, informatics and management teams. We found our goal in the changes.”

The Pantheon Healthcare Group is Europe’s leading platform of independent medical equipment service providers to the public and private healthcare sectors, delivering a broad set of asset management solutions that concentrate on capital procurement and operating expense efficiency while delivering the highest quality service performance throughout the equipment lifecycle. Backed by its ISO 13485 medical device quality certification and a 100% concentrate on Service, the Group continues to expand and improve its Managed Service and Equipment offerings to much better address the calls for of healthcare operators worldwide. The Pantheon Healthcare Group provides diagnostic imaging and clinical services to much more Compared to 650 hospitals and diagnostic imaging healthcare clinics across Europe.

For much more article visit http://www.pantheonhg.com or email info@pantheonhg.com.

You might discover out much more concerning Pantheon offerings for diagnostic imaging maintenance and refurbished units at http://www.mesa-medical.com, for managed equipment services (MES) at http://www.asteral.com or for localised article about our full portfolio of services at http://www.mvs.pl (Poland), http://www.spintech.com.tr (Turkey), http://www.sigil-france.fr (France).

Founded in 1997 by Sergio and Bruno Giglio, Ingegneria Biomedica Santa Lucia (IBSL) is a leader in the biomedical engineering sector. Throughout the last ten years, IBSL further strengthened its placement in the Italian market through the acquisition of D&D Med. Com., Gidea Alta Tecnologia, Ra.se.co and Te.Mo.Sa, which allowed the Company to extend its presence in to Central and South Italy and in Sardinia, likewise widening the range of services offered. IBSL provides management services and corrective maintenance, both preventive and emergency, of a broad portfolio of biomedical equipment. It likewise provides device inspection and plant security within hospitals and inventory management of healthcare equipment. Further, through Gidea Alta Tecnologia and Ra.se.co, IBSL likewise provides reseller services, leasing, installation and maintenance of radiologic equipment, such as DR (digital radiology), CR (computerized radiology) RX, mammography devices, RIS and PACS software and integrated management units for radiology departments. http://www.gruppogiglio.it.

Media Contact:
Benjamin Peltier, Director of Marketing and Communications
+41-91-260-70-18
Email: bpeltier (at) pantheonhg.com

SOURCE MESA Medical Equipment Solutions and Applications

Elsevier Selected to Publish the Official Journal of the National Council of State Boards of Nursing: Journal of Nursing Regulation






PHILADELPHIA, July 30, 2015 /PRNewswire/ —

Elsevier, a world-leading provider of scientific, technical and medical write-up products and services, and the National Council of State Boards of Nursing (NCSBN), have actually announced that Elsevier will certainly publish NCSBN’s flagship journal, Journal of Nursing Regulation.

Journal of Nursing Regulation publishes scholarly articles that get there the science of nursing regulation, promote the mission and vision of NCSBN, and raise communication and collaboration among nurse regulators, educators, practitioners, and the scientific community. The diary supports evidence-based regulation, addresses complications related to patient safety, and highlights current nursing regulatory issues, programs, and projects in the 2 the United States and the worldwide community.

“Our publishing partnership along with Elsevier will certainly take the Journal of Nursing Regulation to the next level,” said Maryann Alexander, PhD, RN, FAAN, that serves as the Editor-in-Chief. “We are thrilled along with this Brand-new partnership.”

“We are pretty excited regarding our collaboration along with the National Council of State Boards of Nursing and are honored to publish their flagship, Journal of Nursing Regulation. We expect functioning with each other carefully along with the editorial group to further the journal’s authorship and enhance its global exposure,” said Mercedes Simoncelli, Elsevier Publisher, Nursing journals.

About Journal of Nursing Regulation 

Journal of Nursing Regulation (JNR), the official diary of the NCSBN, is a quarterly, peer-reviewed, academic and professional journal. It publishes scholarly articles that get there the science of nursing regulation, promote the mission and vision of NCSBN, and raise communication and collaboration among nurse regulators, educators, practitioners, and the scientific community. The diary supports evidence-based regulation, addresses complications related to patient safety, and highlights current nursing regulatory issues, programs, and projects in the 2 the United States and the worldwide community. In publishing JNR, NCSBN’s target is to make and share knowledge related to nursing and various other healthcare regulation across continents and to promote a higher awareness of regulatory complications among every one of nurses. http://www.journals.elsevier.com/journal-of-nursing-regulation

About the National Council of State Boards of Nursing (NCSBN) 

NCSBN is a not-for-profit organization that provides education, service, and research through collaborative leadership to promote evidence-based regulatory excellence for patient safety and public protection.  Membership entails the boards of nursing in the 50 states, the District of Columbia and four U.S. territories. There are 21 associate members. NCSBN is the auto through which boards of nursing act and counsel with each other to give regulatory excellence for public health, safety and welfare. http://www.ncsbn.org

About Elsevier 

Elsevier is a world-leading provider of write-up solutions that raise the performance of science, health, and technology professionals, empowering them to make much better decisions, deliver much better care, and sometimes make groundbreaking discoveries that get there the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions – among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey – and publishes over 2,500 journals, including The Lancet and Cell, and a lot more compared to 33,000 schedule titles, including a variety of iconic reference works. Elsevier is portion of RELX Group plc, a world-leading provider of write-up solutions for professional customers across industries. http://www.elsevier.com

Media contact
Victoria Howard
Elsevier
+1-215-239-3589
v.howard@elsevier.com

SOURCE Elsevier

Frost & Sullivan: Mobile Health may be the Answer for Australia, but is Australia ready?






<!– imageTag: –>
<!– imageTagafter: and imageUrl: http://photos.prnewswire.com/prnvar/20150729/248757?max=400 –>















SYDNEY, July 29, 2015 /PRNewswire/ — In spite of the tremendous development of hospital infrastructure, Australia currently only has actually regarding 4 beds per thousand and a medical workforce of approximately 70,000 working clinicians. A vital issue in Australian healthcare is access to timely and quality care, a problem that can easily potentially be addressed by improving and boosting communication between providers and patients using mobile healthiness (mHealth).

(Photo – http://photos.prnewswire.com/prnh/20150729/248757)

Frost & Sullivan estimates almost 15,000,000 Australians are connected through a smartphone. The increased fee of smartphone penetration among healthcare professionals, coupled along with the Australian government initiatives are factors driving mHealth growth in Australia.

Frost & Sullivan’s brand-new research, Analysis of Mobile healthiness (mHealth) Market in Australia, finds that the market was worth US$1.4 billion in 2014. It is estimated to rise to US$2.18 billion in 2019 at a compound annual growth fee (CAGR) of 9.3 percent throughout this period. The study covers clinical and non-clinical segments mHealth apps and services, yet not devices.

Healthcare providers in Australia are focusing on integrating care across various points of service to a lot more comprehensively understand healthiness issues at both an specific and a population level. Thus, the next generation healthcare delivery system in the country is expected to bring care to homes and offer a a lot more patient centric approach that calls for a higher level of patient engagement in the continuum of care. The emerging out-of-hospital-setting-care trend and the boost of smartphone use among clinicians and patients reveal signs of mHealth propelling in Australia in the near future and bringing care delivery system to a whole brand-new level.

Shalani Andria, Connected healthiness Industry analyst at Frost & Sullivan says healthcare providers and mHealth companies believe mHealth can easily play a crucial role in the Australian healthcare system and envision mobile technologies to play a far a lot more essential role compared to even boosting healthcare access.  mHealth not only improves write-up access across various stakeholders, it likewise encourages the write-up holder to control and take action upon the data. This improves patient engagement and makes consumers a lot more actively involved in managing their health, and has actually been a vital driver for mHealth adoption amongst consumers. While it helps boost patients’ participation in the care delivery system, it likewise has actually the benefit of potentially promoting healthy and balanced behaviours in the population.

Much love most evolving markets, in Australia, mHealth is still at its infant stage, and its full potential in addressing some of the major care delivery challenges is yet to be realised. Consumers are leveraging mHealth apps and related data-analytics services mainly for activity monitoring, health and wellness and fitness purposes. There is some evidence of chronic disease management programs using mHealth both in the public and private sector yet these are still in pilot phases.

Clinical use of mHealth continues to be fraught along with challenges in adoption. The greatest concern is regarding the management of mHealth generated data since there are still gaps in regulations governing data ownership and privacy. Moreover, physicians tend to question some of the claims made by mHealth companies and requirement a federal stamp prior to they think about clinical uses. In the absence of proven clinical applications, mHealth vendors discover it challenging to design a sustainable business model since the big question of that pays for the offering remains unanswered.

“In the healthcare industry, clinicians’ adoption to a brand-new care delivery system is crucial, in the absence of which, the market will certainly have actually a tendency to move towards commoditisation,” explains Andria. “For mHealth in Australia, data security and usage must be addressed at the earliest in order to drive market development.”

Mobile communication is no longer a toy for the gadget-geeks, it has actually become an integral portion of our day-to-day lives and supports all aspects of human life from enabling communication, procuring meals and goods to conducting business. Rapid penetration of mobile communications is revolutionising all industries in Australia including banking, retail and healthcare.

Analysis of Mobile healthiness (mHealth) Market in Australia is portion of the Connected healthiness P8B5-48 (http://www.connectedhealth.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include:

Asia-Pacific Healthcare Industry Outlook, May 2015
Analysis of The Telemedicine Market in Asia-Pacific, July 2015
Pulse of Telehealth, Sep 2014
Asia-Pacific Hospital Outlook 2014, Apr 2015

All studies included in subscriptions offer detailed market opportunities and industry trends evaluated complying with extensive interviews along with market participants.

Analysis of the Mobile healthiness (mHealth) Market in Australia
P8B5-48

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration along with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will certainly make or break today’s market participants. For a lot more compared to 50 years, we have actually been producing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization all set for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough finest practices, changing customer dynamics and emerging economies? Contact us: Start the discussion

Media Contact:

P: +612 82478927
F: +612 92528066
E: djeremiah@frost.com

http://www.frost.com

 

SOURCE Frost & Sullivan

RELATED LINKS
http://www.frost.com

Health 2.0 Announces Inaugural Care Delivery Symposium 2015






SAN FRANCISCO, July 29, 2015 /PRNewswire/ — Good health 2.0 announces the inaugural Innovating Care Delivery Symposium throughout the 9th Annual Good health 2.0 Fall Conference. The Innovating Care Delivery Symposium will certainly bring a few of the most progressive Good health system executives and providers with each other in to one room to discuss exactly how their organizations are embracing Brand-new technologies to deliver much better care. The Symposium and the Conference concentrate on 5 vital means Good health 2.0 is changing care delivery:

  • Transitioning to Value-Based Care: The honest truth of value-based care looms large for several Good health units enjoy Advocate Good health Care in Chicago where sophisticated Brand-new data tools are transforming population health.
  • Tools for Clinical Workflow: Electronic medical records were not the technological leap Good health care needed, yet large providers enjoy Dignity Good health and Mt. Sinai are diligently layering on Brand-new technology to smooth day-to-day life for providers and boost care.   
  • Care Coordination & Collaboration: Technology has actually revolutionized communication for the standard consumer, while medical groups still struggle to efficiently communicate along with each others and patients. Remote monitoring at Kaiser, UCSF, and Minnesota Children’s has actually revealed promise, yet looks uneven at best.    
  • Fostering Brand-new Innovations: Brand-new technology takes time to trickle down in to medical practice, yet as the speed of innovation increases, Good health units enjoy Henry Ford and Providence are producing Brand-new procedures for placing innovation in to practice.  
  • Improving the Patient Experience: The patient experience is most important for Boosting patient outcomes, which is why Good health units are increasingly turning to consumer-oriented tools to advice patients navigate care, communicate along with providers, and actively control their health.     

The collision of Good health 2.0 tools and technologies along with the traditional care delivery system is upon us, and the focal point of that impact is the 9th Annual Good health 2.0 Fall Conference. From attending the Symposium to showcasing a product in front of top hospital executives, presenting a partnership case study, or designing a lunch session for the leaders that will certainly shape care delivery in the years to come, there are a lot of means to engage Good health 2.0’s elite provider audience and mold the conversation. Don’t skip your opportunity to participate. Contact Kim Krueger at kimk@health2con.com to become involved.

About Good health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of Brand-new Good health technologies. Through a global collection of conferences, believed leadership roundtables, developer competitions, pilot programs, and leading market intelligence, Good health 2.0 drives the innovation and collaboration crucial to transform Good health and Good health care.

MEDIA CONTACT
Stephanie Soong
Stephanie@health2con.com

 

SOURCE Good health 2.0

RELATED LINKS
http://www.health2con.com

Judge Pushes Back Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding






<!– imageTag: –>
<!– imageTagafter: and imageUrl: http://photos.prnewswire.com/prnvar/20140714/126845?max=400 –>















ATLANTA, July 29, 2015 /PRNewswire/ — Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that U.S. District Judge Joseph Goodwin in the Southern District of West Virginia (W.Va) pushed spine and altered the single trial that was initially set to start in November. The initial trial that was set included 26 claims from women, however brand-new plaintiffs were added and now it entails 39 women, and the trial has actually been pushed spine to December 7th, according to an post in Reuters. The alterations were earned after data emerged that several of the women involved were implanted along with multiple mesh devices.

Logo – http://photos.prnewswire.com/prnh/20140714/126845  

There are currently over 70,000 cases relating to transvaginal mesh devices. Johnson & Johnson’s Ethicon subsidiary currently faces regarding 33,000 mesh cases (MDL 2327). Because of the higher volume of cases, U.S. District Judge Joseph Goodwin is overseeing seven different multidistrict litigations (MDL) for filed cases versus several mesh manufacturers. Ethicon is merely one of the mesh manufacturers involved, and they have actually lost four cases already.

Chris Janish, CEO of Legal-Bay, commented on the recent announcement of the adjustments to the upcoming trial, “The 39 cases will certainly represent a fantastic opportunity to expedite the J&J and Ethicon section of the transvaginal mesh litigation. To date, J&J has actually not fared well in the trials that they have actually defended, however, they go on to fight over 30,000 claims in which several women victims are waiting for resolution. Unfortunately, several of the women that have actually opted-in to others settlement cases have actually only walked away along with $100K and are still waiting to receive their funds.”

Legal-Bay, a law money get there company, stands prepared to aid women victims along with various lawsuit funding services if they have actually a lawyer already, including obtaining up to a $30K money get there today, or along with tips in finding a qualified transvaginal mesh law firm or mesh lawyer if they have actually not yet filed a claim. To learn much more regarding obtaining settlement funding on your transvaginal mesh case or pre-settlement funding on a pending TVM lawsuit, visit: http://lawsuitssettlementfunding.com/mesh-cases.php 

Legal-Bay’s funding programs are non-recourse lawsuit money advances, likewise known as case funding. None of the programs ought to be considered to be a settlement loan, settlement loans, lawsuit loan, lawsuit loans, pre-settlement loans, or a pre-settlement loan.

Legal-Bay is advising women that have actually had transvaginal mesh or bladder sling complications and/or needed a revision surgery to seek immediate legal counsel to find out if they might have actually a similar transvaginal mesh claim versus any kind of mesh manufacturer. The time to take action is now. To obtain lawsuit funding you ought to have actually a lawyer retained. If you requirement tips along with finding a nationally recognized transvaginal mesh law firm or mesh lawyer, feel free to contact Legal-Bay immediately as time to file a claim could be operating out as each settlement is announced. Legal-Bay’s representatives can easily put you in touch along with a mesh attorney that will certainly give you along with a free legal consultation and you will certainly never ever pay a fee unless your case is successful. Contact Legal-Bay at: http://lawsuitssettlementfunding.com/contact-us.php

If you, or a loved one, are in requirement of lawsuit pre-settlement funding or settlement funding Because of a transvaginal mesh complication and/or would certainly love to speak along with a transvaginal mesh lawyer or mesh law firm, feel free to contact Legal-Bay right now on the company’s 24-hour hotline at: 877.571.0405.

You might likewise fill out an online application to receive a free case evaluation on your case at: http://lawsuitssettlementfunding.com

Legal-Bay LLC (and their related companies) is not a law firm and cannot give legal assistance on a consumer’s case; however, Legal-Bay works along with lawyers involved in mass tort litigations that can easily give a free legal consultation at the consumer’s direction. 

SOURCE Legal-Bay LLC

RELATED LINKS
http://lawsuitssettlementfunding.com

World’s first bilateral hand transplant on child

Surgeons at The Children’s Hospital of Philadelphia (CHOP) joined along with colleagues from Penn Medicine recently to finish the world’s very first bilateral hand transplant on a child. Earlier this month, the surgical group successfully transplanted donor hands and forearms onto eight-year-old Zion Harvey who, several years earlier, had undergone amputation of his hands and feet and a kidney transplant adhering to a serious infection.

Led by L. Scott Levin, M.D., FACS*, Chairman of the Department of Orthopaedic Surgery at Penn Medicine, Director of the Hand Transplantation Program at The Children’s Hospital of Philadelphia, and Professor of Surgery (Division of Plastic Surgery) at the Perelman School of Medicine at The University of Pennsylvania, a 40-member multidisciplinary group of physicians, nurses and various other staff from plastic and reconstructive surgery, orthopaedic surgery, anesthesiology, and radiology, participated in the operation. Attending surgeons from CHOP and from Penn Medicine, along along with Scott H. Kozin, M.D.***, chief of staff for Shriners Hospitals for Children–Philadelphia, collaborated throughout the 10-hour surgical transplantation.

“This surgery was the result of years of training, followed by months of preparing and preparation by a remarkable team,” said Levin. “The victory of Penn’s very first bilateral hand transplant on an adult, performed in 2011, gave us a foundation to adapt the intricate techniques and coordinated plans called for to perform this sort of complex procedure on a child. CHOP is one of the few places worldwide that offer the capabilities vital to push the limits of medicine to provide a Youngster a drastically improved quality of life.”

“This extraordinary accomplishment highlights the world-class abilities of the physicians, nurses, therapists and various other staff that are privileged to serve our patients and their families along with ability and dedication,” said Madeline Bell, president and chief executive officer of The Children’s Hospital of Philadelphia. “I’m especially grateful to Zion’s family that entrusted him or her to our care.”

“The ability to strategy and carry out this sort of surgery is testament to the skill, expertise, surgical innovation, and passion for excellence available here at The Children’s Hospital of Philadelphia,” said N. Scott Adzick, M.D., CHOP’s surgeon-in-chief. “I am very proud of Dr. Levin and his group for their courage, dedication and expertise, and appreciative to Zion and his family, whose bravery and trust in this clinical group is actually inspiring.”

Zion was initially referred to Shriners Hospitals for Youngsters for their expertise in pediatric orthopaedic care, including surgery and rehabilitation. Through a coordinated effort between Shriners Hospitals for Youngsters and CHOP, Zion was evaluated as a feasible recipient of the very first pediatric hand transplant. “The collaborative effort between these institutions was vital to assemble the group and organize the gamers to orchestrate such a complex and demanding procedure that had never been performed on a child.” explained Scott H. Kozin, M.D., chief of staff for Shriners Hospitals for Children–Philadelphia.

Before the surgery could be conducted, it was very first vital to locate a suitable donor, a function coordinated by Gift of Life Donor Program, the nonprofit organ and tissue donor program which serves the eastern half of Pennsylvania, southern Brand-new Jersey and Delaware. “For 41 years, Gift of Life Donor Program has actually partnered along with transplant centers throughout this region to bring innovative transplant procedures to patients in need,” explained Richard Hasz, vice president of Clinical Services for Gift of Life. “As along with all types of transplant, surgeries such as this one could not take place free of the generosity of a donor and a donor family. We thank them for their selflessness and for their gift that Gained this surgery possible.”

“The skills vital to perform such complex surgery at CHOP have actually been acquired from lessons learned over the past 20-plus years of performing pediatric tough organ transplantation,” said Abraham Shaked, M.D., Ph.D., the Eldridge L. Eliason Professor of Surgery and Director, Penn Transplant Institute. “We have actually learned the importance of closely monitoring and managing the activity of the immune system through years of experience, and are hopeful that Zion will certainly take pleasure in fantastic long-term allograft function and a normal life.”

Zion Harvey is a bright and precocious eight-year-old that has actually told his doctors that he cannot wait to someday throw a football. A happy and outgoing child, he has actually adapted well to life free of hands, learning to eat, write and even play video games. He figured out methods to perform most of the activities various other children his age can easily do. Zion received prosthetics for his feet and is able to walk, run and jump along with finish independence. adhering to his latest surgery and after his upcoming rehabilitation, it is expected that Zion will certainly finally get hold of his wish to throw a football along along with a myriad of various other accomplishments to come.

Double hand transplantation is a complex procedure involving numerous surgical and non-surgical components. First, the potential recipient should undergo extensive medical screenings and evaluations Prior to surgery. In this case, the patient’s previous medical condition, adhering to sepsis at an early age, factored in to the decision to perform the transplant. “Zion’s kidney transplant adhering to his infection Gained him or her a candidate for transplant due to the fact that he was already taking anti-rejection medication,” said Benjamin Chang, M.D.**, co-director of CHOP’s Hand Transplant Program as well as associate chief of the Division of Plastic Surgery at Penn Medicine.

During the surgery, the hands and forearms from the donor were attached by connecting bone, blood vessels, nerves, muscles, tendons and skin. The surgical group was divided in to four simultaneous operating teams, two focused on the donor limbs, and two focused on the recipient. First, the forearm bones, the radius and ulna, were connected along with steel plates and screws. Next, microvascular surgical techniques were used to connect the arteries and veins. Once blood flow was established through the reconnected blood vessels, surgeons individually repaired and rejoined each muscle and tendon. Surgeons after that reattached nerves then closed the surgical sites.

Zion continues to receive day-to-day immunosuppressant medications to steer clear of his physique from rejecting the Brand-new limbs, as well as his transplanted kidney. Zion is being cared for by CHOP’s nephrology and kidney transplant team, as well as his hand transplant surgical team. Short article surgery, he spent a week in CHOP’s Pediatric Intensive Care Unit, after that was moved to a medical unit and eventually moved to an inpatient rehabilitation unit where he undergoes rigorous hand therapy several times per day, an necessary step to gaining improvement in function.

The clinical group expects Zion to spend several a lot more weeks in CHOP’s rehabilitation unit, then to be discharged to his estate in Baltimore, Md. Dr. Levin and his group will certainly keep on to follow Zion monthly in the short-term then annually throughout his lifetime.

* L. Scott Levin, M.D., FACS, holds several medical posts. He is Director of the Hand Transplantation Program at The Children’s Hospital of Philadelphia; Chairman of the Department of Orthopaedic Surgery at Penn Medicine; The Paul B. Magnuson Professor of Bone and Joint Surgery at Penn; and Professor of Surgery (Division of Plastic Surgery) at the Perelman School of Medicine at The University of Pennsylvania.

**Dr. Benjamin Chang, M.D., is co-director of CHOP’s Hand Transplantation Program; associate chief of the Division of Plastic Surgery at Penn Medicine; and associate professor of Clinical Surgery at the Perelman School of Medicine at The University of Pennsylvania.

***Scott H. Kozin, M.D., is chief of staff for Shriners Hospitals for Youngsters and clinical professor of the Department of Orthopaedic Surgery at Temple University School of Medicine.

PCA3 Test Now Offered at Dr. Samadi’s Prostate Cancer Center









NEW YORK, July 28, 2015 /PRNewswire/ — Dr. David Samadi’s Prostate Cancer Focus is now offering the PCA3 test for prostate cancer screening.

The PCA3 test is a straightforward urine sample collected complying with a digital rectal exam for the determination of the PCA3 score. Individual for prostate cancer, and, unlike the PSA, this test is not affected by prostate enlargement or others non-cancerous prostate conditions. In combination along with PSA and DRE results, the PCA3 score provides helpful post to advice decide if a biopsy is needed, or Can easily be delayed. It’s more Individual in giving added post regarding the aggressiveness of the cancer if the patient has actually a positive biopsy.

“This Brand-new genetic test is a wonderful next step for some men along with an elevated PSA. The purpose of this tumor marker test is to reduce unnecessary biopsies. Not every elevated PSA translates to the requirement for a biopsy. The PCA3 test was specifically made to handle the criticisms of the PSA being non-Individual to prostate cancer. Combined along with the PSA and DRE, this Brand-new genetic test helps lead to a much more optimized decision to perform the biopsy,” stressed Dr. David Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital in New York City.

The PCA3 test is not meant to replace the PSA test. It is merely yet another tool used to give a much more accurate picture and prediction of whether prostate cancer is present or not. It is intended to be used in combination along with the traditional prostate cancer screening tools (PSA test, DRE) to advice decide whether a prostate biopsy is actually vital in men that are suspected of having prostate cancer. This entails men that have actually a suspicious DRE and/or an elevated PSA and men that have actually had one or much more negative biopsies. If a prostate biopsy determines prostate cancer is present, the PCA3 test might additionally advice predict the risk of tumor development and the aggressiveness of the tumor, which will certainly advice find out exactly how early treatment is needed.

The better the PCA3 score, the much more most likely that prostate cancer will certainly be found in the prostate biopsy. Therefore, a prostate biopsy is recommended. If the PCA3 score is low, a prostate biopsy might be unnecessary or at least delayed for some time. 

If a man’s PSA is elevated, the 4K ScorePCA3, and Prostate Biopsy Can easily further indicate activity about the prostate also as support whether to get hold of a biopsy or not. If a biopsy returns positive, the next step is directing the right prostate cancer treatment for each patient.

Dr. Samadi’s Prostate Cancer Focus is the only Focus in New York City using the revolutionary UroNav Fusion Biopsy System for MRI-Guided Biopsy. An MRI-ultrasound fusion biopsy includes taking an MRI then fusing the data along with real-time ultrasound images for insight on biopsy procedures. The UroNav System combines electromagnetic tracking and navigation along with an onboard computer and a real-time imaging interface in one mobile workstation. The MR/Ultrasound fusion aligns and registers prior diagnostic MR images along with real-time ultrasound images.

Patients newly diagnosed with prostate cancer Can easily contact globe renowned prostate cancer surgeon and urologic oncologist, Dr. David Samadi, for a consultation. Visit ProstateCancer911.com and call 212.365.5000 to established your consultation.

Photo – http://photos.prnewswire.com/prnh/20150728/246610

SOURCE Dr. David Samadi

RELATED LINKS
http://www.roboticoncology.com

CollPlant Names Shomrat Shurtz Senior Director of Business Development









NESS ZIONA, Israel, July 28, 2015 /PRNewswire/ —

CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine firm utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced that Shomrat Shurtz has actually been appointed Senior Director of Company Development, efficient September 20, 2015.

     (Photo: http://photos.prnewswire.com/prnh/20150728/246955 )

Ms. Shurtz brings over 25 years of experience in marketing, regulatory and Company strategy. Prior to joining Collplant, Shomrat served as a Senior Director at Protalix Biotherapeutics Inc. (NYSE: PLX), a biopharmaceutical firm focused on the Progress and production of recombinant therapeutic proteins from plant cell cultures. At Protalix, Shomrat oversaw Protalix’s lead product through its clinical development.  Adhering to its approval and commercialization, Shomrat worked along with Tier 1 pharmaceutical companies as an advertising partner, and served as a liaison along with global essential players, including patient advocacies.

“We are pleased to welcome Shomrat, as she brings considerable commercial, marketing and advocacy affairs experience to CollPlant,” says Yehiel Tal, CEO of CollPlant. “Shomrats’ joining CollPlant is a essential initiative to executing our near-term Strategy to commence sales of Vergenix(TM)STR & Vergenix(TM)FG in Europe, upon receiving CE mark approval for each of these products. Her experience and achievements in launching newly marketed products is a excellent asset to the company.”

About CollPlant 

CollPlant is a clinical-stage regenerative medicine firm leveraging its proprietary, plant-based rhCollagen technology for the Progress and commercialization of tissue repair products, initially for the orthobiologics and advanced wound care markets. The Company’s cutting-edge technology is created to provide and process proprietary recombinant human collagen (rhCollagen), among various other patent-protected recombinant proteins. Provided that CollPlant’s rhCollagen is identical to the type I collagen created by the human body,  it offers considerable conveniences compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and low risk of immune response. The Company’s broad Progress pipeline involves biomaterials indicated for orthopedics and advanced wound healing. Lead products include: VergenixSTR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; VergenixFG (Flowable Gel) wound filler, for treatment of acute and chronic wounds, and; VergenixBVF (Bone Void Filler),  for usage in spinal fusion procedures and trauma. CollPlant’s Company strategy involves proprietary Progress and manufacturing of tissue repair products and their commercialization and distribution, with each other along with leading 3rd parties, alongside alliances along with leading companies for joint development, manufacturing and marketing of extra products.

For a lot more article Concerning CollPlant, visit http://www.collplant.com

Contact at CollPlant:    
Senior Vice President
Tel: +917-322-2216
Email: pschwartz@RxIR.com

SOURCE CollPlant Ltd

Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan






SINGAPORE, July 28, 2015 /PRNewswire/ — Faced along with increasing challenges such as costly treatments and treatments that are palliative very compared to symptomatic, the global healthcare industry today is gradually transforming itself. along with few existing therapies capable of curing or significantly changing the course of a disease, healthcare providers are starting to look towards regenerative medicine as a viable alternative.

Regenerative medicine represents a Brand-new paradigm in human healthiness along with the potential to resolve unmet medical requires by addressing the underlying triggers of diseases.

According to Dr. Jane Andrews, Senior Consultant, Healthcare & Life Sciences, Frost & Sullivan, regenerative medicine has actually the potential to cure diseases enjoy we have actually never seen before.  As a result of this, the market, especially in the area of stem cell therapy, will certainly keep on to experience positive growth, boosted by support from various other sectors.

“Regenerative Medicine initiatives are now attracting Brand-new public and private funding. Despite the fact that Stem Cell Therapy will certainly keep on to be the largest market segment of Regenerative Medicine, cross segment therapies that combine the use of immunology, genetic and stem cell therapy are quickly advancing,” Andrews noted.

Regenerative medicine has actually additionally been an area of interest for major pharma companies, numerous of which have actually set up their own R & D units or have actually acquired stakes / invested in regenerative medicine companies. Major pharmaceutical companies which have actually done so include Pfizer, Johnson & Johnson and Teva Pharma.

Why Stem Cell Therapy?

In this space, cell therapy is the fastest growing segment of regenerative medicine and additionally the largest. Globally, the stem cell therapy market is expected to be worth US $40 billion by 2020 and US $180 billion by 2030.

Cell therapy involves the use of living cells to replace or augment damaged or diseased cells and tissues. It has actually been used for various conditions.  The largest number of marketed cell therapy products is used for the treatment of notably non-healing wounds / skin (46%) and muscular-skeletal injuries (35%). This trend will certainly adjustment as a lot more and stem cell therapy products for cancer and heart disease finish their clinical trials and are approved for market release.

Factors that are driving stem cell manufacturing in the short term include aging populations in necessity of alternative medicine and in the long term, Brand-new evidence that stem cell therapy works. However, an area of concern in the immediate future and long term remains the lack of early stage funding and the inherent variability in ‘living cells’ culture and manufacturing.

“Despite this, it is expected that investors will certainly increasing support for early and mid-stage clinical trials as this fast moving market continues to produce and reveal promise,” explained Andrews.

Regenerative Medicine – The APAC Overview

The Asia-Pacific stem cell market was valued at US $7.10 billion in 2014 and is projected to boost to US $18.71 billion by 2018 at a CAGR of 27.3% for the period.

Sanjeev Kumar, Consultant, Growth Partnership Services, Healthcare, Frost & Sullivan, Asia Pacific attributes the positive growth in APAC to sturdy support from the industry.

“This growth is a result of the increasing regulatory support about stem cell research, advancements in regenerative medicine and the opportunities arising from stem cell therapies,” Kumar noted.

These opportunities include contract research outsourcing and rising patient population along with neurological and various other chronic conditions in the region. Japan, Singapore and South Korea are the frontrunners and are set to dominate the APAC stem cell market in the coming years.

Case Studies:

Japan

Japan is taking the global lead in promoting stem cell research for addressing conditions such as Parkinson’s disease, spinal cord injuries and cardio disorders. In 2013, the Japanese government announced funding of US $1.12 billion for stem cell research on a stem cell type that is free from ethical comes to over embryo harvesting. Through this and various other efforts, it hopes to eventually benefit from the cost savings generated by efficacious stem cell therapies.

South Korea

With some victory in commercializing stem cell therapy products for an open market matched by sturdy government support for R&D, South Korea’s Regenerative Market is a prime area for growth, along with essential opportunities identified in the areas of Cell Therapy, especially in the stem cell therapy for adult stem cells and embryonic stem cells. These with each other along with various other drivers are on monitor to make South Korea one of the top three Regenerative Medicine (RM) markets by 2020.

Singapore

Singapore is considered a haven for stem cell research, owing to its biomedical freedom in terms of favorable laws and sturdy government funding received, making it one of the most favored destinations in APAC for stem cell research. In addition, Singapore has actually a well-organized funding system in place for stem cell research which ensures that public and private funding are evenly divided among companies and researchers. The quickly producing industry has actually additionally seen Singapore secure partnerships along with FDA, UK Stem Cell Foundation, and corporate venture funds such as Novartis.

While North America remains the frontrunner in the Regenerative Medicine industry, the Asia-Pacific market is predicted to offer considerable contributions to the market in the future.

Frost & Sullivan recently held its GIL Webinar – ‘The Brand-new Age of Regenerative Medicine – Why Stem Cell Therapy?’ on 28 July, 2015 in Singapore. If you would certainly enjoy to be notified of any upcoming healthcare-related briefings in APAC, please email melissa.tan@frost.com.

To view the webinar, please visit https://www.brighttalk.com/webcast/5565/163681

Please note this complimentary briefing needs a one-time registration on our web conferencing partner’s website BrightTalk. 

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration along with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will certainly make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two essential elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, occupation ideal practices as well as our global footprint of a lot more compared to 40 offices.

For a lot more compared to 50 years, we have actually been producing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization all set for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough ideal practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Media Contact:

P: +65 6890 0926
F: +65 6890 0999
E: melissa.tan@frost.com

http://www.frost.com

 

SOURCE Frost & Sullivan

RELATED LINKS
http://www.frost.com